Synapse

← Brett P. Monia

Papers by Brett P. Monia

Page 3 · newest first

  1. Structure−Activity Relationship Study on a Simple Cationic Peptide Motif for Cellular Delivery of Antisense Peptide Nucleic AcidJournal of Medicinal Chemistry · 2005
  2. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice†Hepatology · 2005
  3. Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid AntagonismDiabetes · 2005
  4. Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious miceView · 2005
  5. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotidesBlood · 2004
  6. Bcl-2 Sustains Increased Mucous and Epithelial Cell Numbers in Metaplastic Airway EpitheliumAmerican Journal of Respiratory and Critical Care Medicine · 2004
  7. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense down-regulation of exon 5 alters target gene expression and inhibits cell survivalMolecular Cancer Therapeutics · 2004
  8. Role of resistin in diet-induced hepatic insulin resistanceJournal of Clinical Investigation · 2004
  9. Role of resistin in diet-induced hepatic insulin resistanceJournal of Clinical Investigation · 2004
  10. Mcl-1 Is a Novel Therapeutic Target for Human SarcomaClinical Cancer Research · 2004
  11. Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitorsJournal of Clinical Investigation · 2004
  12. Antisense Oligonucleotide Targeting of Raf-1Clinical Cancer Research · 2004
  13. Reduction in Glucagon Receptor Expression by an Antisense Oligonucleotide Ameliorates Diabetic Syndrome indb/dbMiceDiabetes · 2004
  14. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effectMolecular Cancer Therapeutics · 2004
  15. Evaluation of C-5 Propynyl Pyrimidine-Containing Oligonucleotides In Vitro and In VivoAntisense and Nucleic Acid Drug Development · 2003
  16. Interleukin-2 family cytokines stimulate phosphorylation of the Pro-Ser-Pro motif of Stat5 transcription factors in human T cells: resistance to suppression of multiple serine kinase pathwaysJournal of Leukocyte Biology · 2002
  17. Regulation of Lipoprotein Lipase by Protein Kinase Cα in 3T3-F442A AdipocytesJournal of Biological Chemistry · 2002
  18. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic miceProceedings of the National Academy of Sciences · 2002
  19. Protein Tyrosine Phosphatase 1B Reduction Regulates Adiposity and Expression of Genes Involved in LipogenesisDiabetes · 2002
  20. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cellsBlood · 2002
  21. Specific Inhibition of PTEN Expression Reverses Hyperglycemia in Diabetic MiceDiabetes · 2002
  22. Bcl‐XL is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapyInternational Journal of Cancer · 2002
  23. Bcl-xL Antisense Oligonucleotides Chemosensitize Human Glioblastoma CellsChemotherapy · 2002
  24. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancerBritish Journal of Cancer · 2001
  25. Relaxin Positively Regulates Matrix Metalloproteinase Expression in Human Lower Uterine Segment Fibroblasts Using a Tyrosine Kinase Signaling PathwayEndocrinology · 2001
  26. In vivo suppression of Bcl‐XL expression facilitates chemotherapy‐induced leukaemia cell death in a SCID/NOD‐Hu modelBritish Journal of Haematology · 2001
  27. In Vitro and In Vivo Inhibition of Interleukin (IL)-5–Mediated Eosinopoiesis by Murine IL-5R α Antisense OligonucleotideAmerican Journal of Respiratory Cell and Molecular Biology · 2001
  28. A Phase I trial of h-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinomaCancer · 2001
  29. Antisense Inhibition of Membrane-Bound Human Interleukin-5 Receptor-α Chain Does Not Affect Soluble Receptor Expression and Induces Apoptosis in TF-1 CellsAntisense and Nucleic Acid Drug Development · 2000
  30. Role of Ras Isoforms in the Stimulated Proliferation of Human Renal Fibroblasts in Primary CultureJournal of the American Society of Nephrology · 2000
  31. Inhibition of C-Raf Expression by Antisense Oligonucleotides Extends Heart Allograft Survival in Rats1Transplantation · 2000
  32. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor modelInternational Journal of Cancer · 2000
  33. Inhibition of Antigen-Induced Eosinophilia and Late Phase Airway Hyperresponsiveness by an IL-5 Antisense Oligonucleotide in Mouse Models of AsthmaThe Journal of Immunology · 2000
  34. Antisense Approaches for the Treatment of CancerCancer Investigation · 2000
  35. Distinct Roles of JNKs/p38 MAP Kinase and ERKs in Apoptosis and Survival of HCD-57 Cells Induced by Withdrawal or Addition of ErythropoietinBlood · 1999
  36. Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemiaProceedings of the National Academy of Sciences · 1999
  37. Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)Journal of Clinical Oncology · 1999
  38. A Role for c-Raf Kinase and Ha-Ras in Cytokine-mediated Induction of Cell Adhesion MoleculesJournal of Biological Chemistry · 1998
  39. Biophysical and antisense properties of oligodeoxynucleotides containing 7-propynyl-, 7-iodo- and 7-cyano-7-deaza-2-amino-2'-deoxyadenosinesNucleic Acids Research · 1998
  40. PKC-ε Is Required for Mechano-sensitive Activation of ERK1/2 in Endothelial CellsJournal of Biological Chemistry · 1997
  41. Cholesterol Conjugated Uniform and Gapmer Phosphorothioate Oligonucleotides Targeted Against PKC-α and C-rafGene ExpressionNucleosides and Nucleotides · 1997
  42. Protein Kinase C-ζ Mediates Angiotensin II Activation of ERK1/2 in Vascular Smooth Muscle CellsJournal of Biological Chemistry · 1997
  43. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C- raf kinase supports an antisense mechanism of action in vivoProceedings of the National Academy of Sciences · 1996
  44. Antisense Oligonucleotides Demonstrate a Dominant Role of c-Ki-RAS Proteins in Regulating the Proliferation of Diploid Human FibroblastsJournal of Biological Chemistry · 1996
  45. Destabilization of Raf-1 by Geldanamycin Leads to Disruption of the Raf-1–MEK–Mitogen-Activated Protein Kinase Signalling PathwayMolecular and Cellular Biology · 1996
  46. Second-generation antisense oligonucleotides: structure—activity relationships and the design of improved signal-transduction inhibitorsBiochemical Society Transactions · 1996
  47. Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha-Journal of Biological Chemistry · 1996
  48. Second Generation of Antisense Oligonucleotides: From Nuclease Resistance to Biological Efficacy in AnimalsCHIMIA International Journal for Chemistry · 1996
  49. 2‘-O-Aminopropyl Ribonucleotides: A Zwitterionic Modification That Enhances the Exonuclease Resistance and Biological Activity of Antisense OligonucleotidesJournal of Medicinal Chemistry · 1996
  50. Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexesBiochemical Journal · 1995